For patients with DCIS, risk of death higher for women under 35, black women
the ONA take:
Women diagnosed with ductal carcinoma in situ have a 20-year breast cancer-specific death rate of 3.3%, with a higher death rate among women diagnosed before age 35 and black women, according to a study published online ahead of print in JAMA Oncology.
For the study, researchers analyzed data from 108,196 women diagnosed with ductal carcinoma in situ of the breast included in the Surveillance, Epidemiology and End Results (SEER) database and compared their risk of dying of breast cancer with that of women in the general population.
Results showed that the 10-year breast cancer-specific death rate after cancer diagnosis was 1.1% and the 20-year rate was 3.3%. Researchers found that women who had a ductal carcinoma in situ diagnosis have a 1.8 times higher risk of death compared those in the general population.
The study also demonstrated that age at diagnosis and black ethnicity were risk factors for death following a ductal carcinoma in situ diagnosis.
Women diagnosed with ductal carcinoma in situ have a 20-year breast cancer-specific death rate of 3.3%.
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Immune Thrombocytopenia (Fact Sheet)
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|